Signs and Symptoms, Respiratory
Conditions
Keywords
Busulfan, pharmacokinetic, respiratory function assessment, Busulfan pharmacokinetic and respiratory function tests
Brief summary
Recently, several conditioning regimens did not include total body irradiation (TBI) anymore, especially in the case of young children due to cognitive sequelae and late effects on growth and height. Thus, such effective chemotherapy conditioning regimens were developed to avoid these complications. Busulfan is one of the major drugs used in these treatments, but, is also administered in high dose chemotherapy followed by autograft. In both situations, long term pulmonary side effects were diagnosed in a few cases. Even if the occurrence is not very frequent, the clinical management is a real challenge regarding the reduced quality of life and life expectancy of these patients. Up to now, no correlation was done between respiratory sequelae and busulfan pharmacokinetics. Hence, in the investigators' pediatric onco-hematological unit, a prospective study will begin and last three years to assess the respiratory side effects due to busulfan and their potential links with individual drug pharmacokinetic measures. These results will be compared to patients treated with TBI during the same period of time.
Interventions
DRUGbusulfan
5mg/kg/day (oral route : 4 doses/day for 4 days)
PROCEDURErespiratory function tests
respiratory function tests before allograft or autograft and at several times in the follow up (3, 6, 12, 18 and 24 months).
PROCEDUREpharmacokinetics, done during the treatment
12 blood collections : * after 1st Busulfan taken : t0; t0 + 30 mn; t0 + 1h; t0 + 2h ; t0 + 3h ; t0 + 4h ; t0 + 5 h. * 3 hours after 2nd taken of Busulfan * 3 hours after 3rd taken of Busulfan * 3 hours after 4th taken of Busulfan * 3 hours after 5th taken of Busulfan * 3 hours after 6th taken of Busulfan.
Sponsors
University Hospital, Strasbourg, France
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
3 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* Patients above 3 years old treated by busulfan or TBI in their conditioning regimens before allograft or busulfan in high dose chemotherapeutic regimens followed by autograft will be included after parents informed assent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determination of respiratory side effect frequency in the two years follow up of allograft or autograft treated with busulfan | before allograft or autograft and at several times in the follow up (3, 6, 12, 18 and 24 months). |
Secondary
| Measure | Time frame |
|---|---|
| Comparison to respiratory side effect frequency with TBI conditioning regimen | before allograft or autograft and at several times in the follow up (3, 6, 12, 18 and 24 months). |
| Busulfan pharmacokinetics | after 1st Busulfan taken : t0; t0 + 30 mn; t0 + 1h; t0 + 2h ; t0 + 3h ; t0 + 4h ; t0 + 5 h ; 3 h after 2nd Busulfan taken ; 3 hours after 3rd Busulfan taken ; 3 h after 4st Busulfan taken ;3 h after 5st Busulfan taken ;3 h after 6st Busulfan taken |
| Establish a potential link between respiratory side effects and busulfan pharmacokinetics | — |
Countries
France
Contacts
Primary ContactPatrick Lutz, MD
Backup ContactNatacha Entz-Werle, MD
Outcome results
None listed